- 全部删除
您的购物车当前为空
Rezivertinib (BPI-7711) 是一种可口服且具有选择性和高效性的酪氨酸激酶 (EGFR) 抑制剂 ,具有抗肿瘤活性,可用与研究中枢神经系统疾病。


为众多的药物研发团队赋能,
让新药发现更简单!
Rezivertinib (BPI-7711) 是一种可口服且具有选择性和高效性的酪氨酸激酶 (EGFR) 抑制剂 ,具有抗肿瘤活性,可用与研究中枢神经系统疾病。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 248 | In stock | |
| 5 mg | ¥ 579 | In stock | |
| 10 mg | ¥ 953 | In stock | |
| 25 mg | ¥ 1,880 | In stock | |
| 50 mg | ¥ 3,170 | In stock | |
| 100 mg | ¥ 4,530 | In stock | |
| 200 mg | ¥ 6,380 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 618 | In stock |
Rezivertinib 相关产品
| 产品描述 | Rezivertinib (BPI-7711) is an orally available, selective and potent inhibitor of tyrosine kinase (EGFR) with antitumor activity for central nervous system disorders. |
| 靶点活性 | HCC827 cells:6.8 nM (GI50), NCI-H1975 cells:22 nM (GI50), A431 cells:>1000 nM (GI50), PC9 cells:13.3 nM (GI50) |
| 体外活性 | Rezivertinib 可选择性地抑制表皮生长因子受体突变细胞系的细胞增殖: PC9(GI50=13.3 nM)、HCC827(GI50=6.8 nM)、NCI-H1975(GI50=22 nM)和 A431(GI50>1000 nM)。[1] |
| 体内活性 | Rezivertinib 口服14天6.25-25 mg/kg/天,表现出显著的肿瘤消退效果。 |
| 别名 | 瑞齐替尼, BPI-7711, BPI7711 |
| 分子量 | 486.57 |
| 分子式 | C27H30N6O3 |
| CAS No. | 1835667-12-3 |
| Smiles | O=C(C=C)NC1=CC(NC=2N=CC=C(N2)C3=CN(C=4C=CC=CC34)C)=C(OC)C=C1OCCN(C)C |
| 存储 | store at low temperature,keep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 100 mg/mL, (205.52 mM.), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
溶液配制表 | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
评论内容